Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BrightEdge serves as the innovation and impact investment arm of the American Cancer Society (ACS), established in 2018. The organization is dedicated to catalyzing scientific, social, and sustainable impact across the continuum of cancer care. By leveraging ACS's extensive history in cancer research and patient support, BrightEdge invests in scalable solutions that address critical unmet needs in cancer care.
As of 2024, BrightEdge has deployed $52 million across 22 companies, with an active portfolio of 16 companies. The firm operates globally, focusing on early-stage investments in healthcare, biotech, and digital health sectors. BrightEdge's mission is to generate financial returns that diversify ACS's funding sources while also enhancing patient outcomes and access to care.
BrightEdge has established a significant presence in the venture capital landscape, particularly in cancer care. Their commitment to addressing health disparities and advancing scientific discovery is reflected in their investment strategy, which emphasizes technology-enabled solutions and science-based medicines.
BrightEdge invests in early-stage, for-profit companies that develop patient-centric solutions in cancer care. Their investment strategy encompasses therapeutics, diagnostics, devices, and digital health technologies. The firm operates across various funding stages, including pre-seed, seed, seed+, and Series A, indicating a strong commitment to nurturing early-stage innovations.
The organization employs a Cancer Impact Investment Framework to evaluate potential investments, focusing on innovations that enhance patient outcomes and access to care. BrightEdge prioritizes investments that align with 10 ACS mission priority areas, including cancer health equity, survivorship, and clinical trial access. Their approach aims to accelerate the commercialization of solutions that address critical areas such as prevention, early detection, and treatment adherence.
BrightEdge supports a diverse range of pioneering companies in cancer care, with a current portfolio of 16 companies as of 2024. Notable portfolio companies include:
Since its inception, BrightEdge has deployed $52 million across 22 companies, focusing on innovations that enhance patient outcomes and access to care. The firm’s portfolio reflects its commitment to addressing critical unmet needs in cancer care through scalable solutions.
Steve Curtis, PhD - Managing Director: Steve has extensive experience in venture capital and healthcare innovation, previously working with leading firms in the biotech sector.
Farnaz Bakhshi, PhD - Director, Innovation: Farnaz specializes in early-stage investments in healthcare and has a strong background in cancer research.
Amy Berg - Principal, Philanthropy: Amy focuses on building partnerships and securing funding for BrightEdge's initiatives, leveraging her experience in nonprofit management.
Eunice Chapon, JD - Director, Impact: Eunice brings expertise in legal and regulatory aspects of healthcare investments, ensuring compliance and strategic alignment with ACS's mission.
Calum Daly - Investment Fund and Business Analyst: Calum analyzes market trends and investment opportunities, contributing to BrightEdge's strategic decision-making.
Barbra Kocsis, MBA, MA - Director, Operations: Barbra oversees operational efficiency and program implementation, drawing on her background in healthcare management.
Nate Macht, MBA - Investment and Innovation Senior Analyst: Nate evaluates potential investments and supports portfolio companies in scaling their operations.
Ana Rojas - Executive Assistant: Ana provides administrative support and coordination for the BrightEdge team.
Bianca Scimemi - Entrepreneurs Program Manager: Bianca manages the BrightEdge Entrepreneurs Program, focusing on supporting first-time entrepreneurs in cancer research.
Michka Sharpe, PhD - Senior Associate, Investments: Michka conducts due diligence on potential investments and supports the investment team in portfolio management.
Nishant Uppal, MD, MBA - Healthcare Impact Consultant: Nishant advises on healthcare trends and patient impact, ensuring alignment with BrightEdge's mission.
Jess Miciak, PhD - Associate, Investments: Jess assists in evaluating investment opportunities and conducting market research.
Ryan Margolis, PhD - Texas Accelerator Program Manager: Ryan oversees the Texas Accelerator Program, focusing on fostering innovation in cancer care.
Josh Zail - Impact Program Manager: Josh manages initiatives aimed at maximizing the social impact of BrightEdge's investments.
To pitch BrightEdge, founders should submit their proposals through the official website at acsbrightedge.org. The pitch deck should include a comprehensive overview of the technology, the team’s qualifications, and the expected impact on cancer care. BrightEdge prefers clear, concise presentations that highlight the innovation's potential to improve patient outcomes.
While specific response times are not disclosed, founders can expect timely feedback on their submissions. Warm introductions are beneficial but not mandatory for initial outreach.
BrightEdge offers several programs designed to support early-stage cancer-fighting entrepreneurs. The BrightEdge Entrepreneurs Program is an accelerator aimed at training and equipping first-time entrepreneurs to launch companies that progress cancer research discoveries.
The Project HEALTH program focuses on startups addressing disparities in cancer care, providing education sessions, funding opportunities, and mentorship to help these companies succeed.
In 2024, BrightEdge announced a new investment in Signify Bio, a developer of in vivo therapeutics. This investment aligns with their mission to support innovative solutions in cancer care.
BrightEdge also formed a partnership with Third Rock Ventures to drive oncology innovation, enhancing their ability to support early-stage companies in the sector.
Additionally, BrightEdge launched the Project HEALTH accelerator, which targets startups addressing disparities in cancer care, providing $50,000 via SAFE note and tailored mentorship opportunities.
What are BrightEdge's investment criteria?
BrightEdge focuses on early-stage, for-profit companies that develop patient-centric solutions in cancer care. Their investments span therapeutics, diagnostics, devices, and digital health technologies.
How can I apply or pitch to BrightEdge?
Founders can pitch BrightEdge through their website at acsbrightedge.org. It is recommended to include a clear description of the technology, its impact on cancer care, and the team’s background in the pitch deck.
What makes BrightEdge different from other investors?
BrightEdge is unique in its dual focus on financial returns and social impact, specifically targeting innovations that address critical unmet needs in cancer care. Their affiliation with the American Cancer Society provides a strong network and resources for portfolio companies.
What is the geographic scope of BrightEdge's investments?
BrightEdge operates globally, investing in companies that develop solutions for cancer care, regardless of their location.
What is the typical check size for investments?
While specific check sizes are not disclosed, BrightEdge participates in funding rounds from pre-seed to Series A, indicating a range of investment amounts tailored to the needs of early-stage companies.
What kind of support do portfolio companies receive?
BrightEdge provides ongoing support to portfolio companies, including mentorship, resources, and access to initiatives like the Project HEALTH accelerator, which focuses on addressing disparities in cancer care.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.